Organovo Holdings Inc  

(Public, NASDAQ:ONVO)   Watch this stock  
2.35
-0.03 (-1.26%)
After Hours: 2.30 -0.05 (-2.13%)
Jul 27, 6:59PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.32 - 2.42
52 week 2.30 - 4.99
Open 2.39
Vol / Avg. 0.00/698,314.00
Mkt cap 248.22M
P/E     -
Div/yield     -
EPS -0.39
Shares 105.63M
Beta 2.96
Inst. own 24%
Aug 9, 2017
Q1 2018 Organovo Holdings Inc Earnings Call - 5:00PM EDT - Add to calendar
Aug 9, 2017
Q1 2018 Organovo Holdings Inc Earnings Release - 9:30AM EDT - Add to calendar
Jun 8, 2017
Organovo Holdings Inc at Jefferies Healthcare Conference
Jun 7, 2017
Q4 2017 Organovo Holdings Inc Earnings Call - Webcast
Jun 7, 2017
Q4 2017 Organovo Holdings Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2017
Net profit margin -1312.44% -908.91%
Operating margin -1316.26% -911.94%
EBITD margin - -884.77%
Return on average assets -58.83% -56.23%
Return on average equity -64.15% -61.74%
Employees 113 -
CDP Score - -

Address

6275 Nancy Ridge Drive Suite 110
SAN DIEGO, CA 92121
United States - Map
+1-858-5509994 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Organovo Holdings, Inc. is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.

Officers and directors

Keith E. Murphy Chairman of the Board
Age: 44
Bio & Compensation  - Reuters
Taylor J. Crouch President, Chief Executive Officer
Age: 57
Bio & Compensation  - Reuters
Eric Michael David M.D. J.D. Executive Vice President - Pre-Clinical Development, Chief Strategy Officer
Age: 48
Bio & Compensation  - Reuters
Sharon Collins Presnell Ph.D. Chief Scientific Officer
Age: 47
Bio & Compensation  - Reuters
Jennifer Kinsbruner Bush J.D. Compliance Officer, General Counsel, Corporate Secretary
Age: 41
Bio & Compensation  - Reuters
Paul Gallant General Manager
Age: 51
Bio & Compensation  - Reuters
Robert F. Baltera Jr. Lead Independent Director
Age: 51
Bio & Compensation  - Reuters
James T. Glover Independent Director
Age: 66
Bio & Compensation  - Reuters
Richard A. Heyman Ph.D. Independent Director
Age: 59
Bio & Compensation  - Reuters
Tamar D. Howson Independent Director
Age: 68
Bio & Compensation  - Reuters